Phase 1 Clinical Trial to Evaluate the Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis.
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Sep 2017
At a glance
- Drugs Umbilical cord mesenchymal stem cell therapy-Kangstem Holdings (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors Kangstem Biotech
- 01 Sep 2017 Planned initiation date changed from 1 Nov 2016 to 1 Dec 2017.
- 30 Sep 2016 New trial record